RADIOGARDASE(Heyl Chem.-pharm. Fabrik GmbH & Co. KG)(七)
e establishment of a patient triage site, patient decontamination area, and a contaminated or “dirty” material dumpsite. Proper labeling, handling, and disposal of contaminated material needs to be established and followed.
2.Manage the patient to minimize further injury and to stabilize before external decontamination.
3.Establish if the patient suffers from a single or combined injury (e.g., radiation, burns, trauma, chemical, biological, etc.) and whether the contaminant may be internalized.
The route of entry of the radiation contaminant needs to be identified and recorded. The route of entry will determine other treatment methods needed (e.g., wound debridement or stomach lavage if ingested). Patients need to be triaged based on their injuries and the level and type of contamination.
4.A quantitative baseline of the internalized contamination of 137 Cs should be obtained by appropriate whole-body counting and/or by bioassay (e.g., Biodosimetry), or feces/urine sample whenever possible to obtain the following type of information to establish an elimination curve:
◦Estimated internalized radiation contamination of 137 Cs, and
◦Rate of measured elimination of radiation in the feces.
Further considerations for thallium contamination (radioactive and non-radioactive)
General therapy guidelines for thallium contamination should follow the radioactive decontamination procedures listed above for 137 Cs, except that there is no need for radiation safety precautions when treating patients contaminated with non-radioactive thallium. For both radioactive and non-radioactive thallium contamination, a quantitative baseline of the internalized thallium contamination should be ascertained by appropriate whole body counting and/or by bioassay whenever possible.
Patients should also have weekly CBC, serum chemistry and electrolytes while under treatment. The response to other orally administered medications should be closely monitored. (See Drug-Drug Interactions.)
In cases of severe thallium intoxication, additional types of elimination treatment may be necessary, such as:
◦Induced emesis, followed by gastric intubation and lavage.
◦Forced diuresis until urinary thallium excretion is less than 1 mg/24h.
◦Charcoal hemoperfusion may be useful during the first 48 hours after thallium ingestion (biodistribution phase).
◦Hemodialysis has also been reported to be effective in thallium intoxication.
Considerations for multiple contaminant exposure (radioactive and non-radioactive)
In patients who have contamination with multiple or unknown radioactive isotopes, additional decontamination and treatment procedures may be needed.
HOW SUPPLIEDRadiogardase is supplied as 0.5 gram blue powder in gelatin capsules for oral administration. The dark blue capsules are imprinted with the light blue inscription: PB. It is packaged in white plastic containers (HDPE) with a childproof closure and tamper-evident seal. The containers contain 36 capsules each.
Instruction for opening the containerOpen the container as shown on the picture:
Step 1: Press firmly on the closure.
Step 2: Twist the closure while pressing.
The product is manufactured by Haupt Pharma Berlin GmbH for distribution by HEYL Chemisch-pharmazeutische Fabrik GmbH and Co. KG, Berlin.
NDC 58060-002-02
Storage
Store in the dark at 25°C ( |
